Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncogenic Fusion and Co-expression Target Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ZHX1-C8orf76 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ZHX1-C8orf76 Fusion Recombinant Protein High purity (>95%), Endotoxin Controlled. Sequence Verified. Theoretical MW optimized for assay stability. |
View ZHX1-C8orf76 Products |
| Gene Delivery | ZHX1-C8orf76 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and intracellular localization assays. |
View ZHX1-C8orf76 Products |
| Benchmark Ab | Anti-ZHX1-C8orf76 Recombinant Antibody Sequence-verified positive control for Western Blot, Immunoprecipitation, and IHC. |
View ZHX1-C8orf76 Products |
| Validator | ZHX1-C8orf76 siRNA Set Target-specific knockdown verification for functional rescue and specificity assays. |
View ZHX1-C8orf76 Products |
| Related Target A | ZHX1 (Zinc Fingers and Homeoboxes 1) Wild-type control to assess fusion-specific selectivity and eliminate off-target liabilities. |
View ZHX1 Products |
| Related Target B | C8orf76 (Chromosome 8 Open Reading Frame 76) Somatic co-amplification partner implicated in gastric and hepatocellular carcinoma proliferation. |
View C8orf76 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Fusion-specific epitope targeting | Recombinant proteins designed with precise junction-spanning sequences, HEK293 expressed for native conformation. |
| Intracellular target validation | High-titer Lentiviral vectors optimized for stable expression in hard-to-transfect cancer cell lines. |
| Lack of validated controls | Sequence-verified biosimilar-grade benchmark antibodies included in the catalog. |
| Off-target profiling against wild-type | Parallel screening panels featuring separate wild-type ZHX1 and C8orf76 recombinant proteins. |
Live ZHX1-C8orf76 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ZHX1-C8orf76 therapeutics is intensifying, with major players shifting focus from traditional systemic therapies to targeted small-molecule inhibitors, PROTACs, and RNA-based therapeutics. As first-generation oncogenic fusion therapies reach the clinic, the next wave of R&D is targeting the specific protein-protein interaction (PPI) interface and downstream transcriptional machinery of the ZHX1-C8orf76 complex.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule / PPI Inhibitors | Biotech Startups, Academic Consortia | Hepatocellular Carcinoma, Gastric Cancer | Selectivity Assay (Need Mutant vs WT Proteins to avoid systemic wild-type toxicity) |
| PROTAC / Degraders | Targeted Protein Degradation Pioneers | Solid Tumors, Refractory Gastrointestinal Cancers | Intracellular Degradation Assay (Need Lentivirus for Stable Cell Line generation) |
| RNAi / ASO Therapeutics | RNA Therapeutics Specialists | Advanced Solid Tumors with 8q24 Amplification | In vitro Knockdown Validation (Need validated siRNA Sets and qPCR controls) |